Michael Secora
Chief Corporate Development Officer & CFODr. Michael Secora, Ph.D. is Chief Corporate Development Officer and Chief Financial Officer of Iambic Therapeutics, Inc. from January 2025. He, Ph.D., served as Chief Financial Officer at Recursion Pharmaceuticals, Inc. since March 2020 until November 20, 2024. At Recursion, he led finance, communications and investor relations activities as well as corporate strategy for translating value both internally and externally across Recursion's internal pipeline, external partnerships and data. Dr. Secora led efforts related to Recursion's entering collaborations with Bayer, Roche-Genentech, NVIDIA, Google, Tempus and others; combining with Exscientia (EXAI), Cyclica, Valence and Vium; and raising over 1.3 billion for Recursion across both private and public fundraising rounds. Dr. Secora worked at Laurion Capital Management, as an asset manager based in New York City from July 2010 to February 2020, where he was Managing Director and Head of Capital Markets and Venture. During his time at Laurion, he developed, executed and managed fundamentally grounded investment strategies as well as built business partnerships and technological infrastructure for investing in event-driven, fundamental and macroeconomic contexts. At Laurion Capital Management, Dr. Secora was active in venture, crossover, capital markets, public and special situations investing particularly within emerging technologies and the life sciences. Dr. Secora received his Ph.D. from Princeton University in Applied and Computational Mathematics and B.S. in Mathematics and Physics from Massachusetts Institute of Technology.
公司职务
- 公司名称Iambic Therapeutics, Inc.股票代码IAM职务Chief Corporate Development Officer & CFO
